Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size

S. Lewis; A. Barry; M. A. Hawkins

doi:10.1016/j.clon.2022.02.021

Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size

S. Lewis
, A. Barry
, M. A. Hawkins

University Health Network
University of Toronto
University College London

Research output: Contribution to journal › Article › peer-review

Abstract

The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.

Original language	English
Pages (from-to)	e195-e209
Journal	Clinical Oncology
Volume	34
Issue number	5
DOIs	https://doi.org/10.1016/j.clon.2022.02.021
Publication status	Published - May 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Dose fractionation
External beam radiotherapy (EBRT)
Hepatocellular carcinoma (HCC)
Hypofractionation
Radiotherapy
Stereotactic body radiotherapy (SBRT)

Access to Document

10.1016/j.clon.2022.02.021

Cite this

@article{227b5cbf2ab1441e8c7b74517a54e53e,

title = "Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size",

abstract = "The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30\%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.",

keywords = "Dose fractionation, External beam radiotherapy (EBRT), Hepatocellular carcinoma (HCC), Hypofractionation, Radiotherapy, Stereotactic body radiotherapy (SBRT)",

author = "S. Lewis and A. Barry and Hawkins, \{M. A.\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Royal College of Radiologists",

year = "2022",

month = may,

doi = "10.1016/j.clon.2022.02.021",

language = "English",

volume = "34",

pages = "e195--e209",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size

AU - Lewis, S.

AU - Barry, A.

AU - Hawkins, M. A.

PY - 2022/5

Y1 - 2022/5

N2 - The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.

AB - The use of stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) has increased over the years. Several prospective studies have demonstrated its safety and efficacy, and randomised trials are underway. The advancement in technology has enabled the transition from three-dimensional conformal radiotherapy to highly focused SBRT. Liver damage is the primary limiting toxicity with radiation, with the incidence of grade 3 varying from 0 to 30%. The reported radiotherapy fractionation schedule for HCC, and in practice use, ranges from one to 10 fractions, based on clinician preference and technology available, tumour location and tumour size. This review summarises the safety and efficacy of various SBRT fractionation schedules for HCC.

KW - Dose fractionation

KW - External beam radiotherapy (EBRT)

KW - Hepatocellular carcinoma (HCC)

KW - Hypofractionation

KW - Radiotherapy

KW - Stereotactic body radiotherapy (SBRT)

UR - https://www.scopus.com/pages/publications/85126532536

U2 - 10.1016/j.clon.2022.02.021

DO - 10.1016/j.clon.2022.02.021

M3 - Article

C2 - 35314091

AN - SCOPUS:85126532536

SN - 0936-6555

VL - 34

SP - e195-e209

JO - Clinical Oncology

JF - Clinical Oncology

IS - 5

ER -

Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this